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Abstract
Because disease-associated microglia (DAM) and disease-associated astrocytes (DAA) are
involved in the pathophysiology of Alzheimer’s disease (AD), we systematically identified
molecular networks between DAM and DAA in order to uncover novel therapeutic targets for AD.
Specifically, we develop a network-based methodology that leverages single-cell/nucleus RNAsequencing data from both transgenic mouse models and AD patient brains, as well as drugtarget network, metabolite-enzyme associations, the human protein-protein interactome, and
large-scale longitudinal patient data. Through this approach, we find both common and unique
gene network regulators between DAM (i.e., PAK1, MAPK14, and CSF1R) and DAA (i.e.,
NFKB1, FOS, and JUN) that are significantly enriched by neuro-inflammatory pathways and
well-known genetic variants (i.e., BIN1). We identify shared immune pathways between DAM
and DAA, including Th17 cell differentiation and chemokine signaling. Lastly, integrative
metabolite-enzyme network analyses suggest that fatty acids and amino acids may trigger
molecular alterations in DAM and DAA. Combining network-based prediction and retrospective
case-control observations with 7.2 million individuals, we identify that usage of fluticasone (an
approved glucocorticoid receptor agonist) is significantly associated with a reduced incidence of
AD (hazard ratio (HR) = 0.86, 95% confidence interval (CI) 0.83-0.89, p<1.0×10-8). Propensity
score-stratified cohort studies reveal that usage of mometasone (a stronger glucocorticoid
receptor agonist) is significantly associated with a decreased risk of AD (HR=0.74, 95% CI 0.680.81, p<1.0×10-8) compared to fluticasone after adjusting age, gender, and disease
comorbidities. In summary, we present a network-based, multimodal methodology for singlecell/nucleus genomics-informed drug discovery and has identified fluticasone and mometasone
as potential treatments in AD.
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Introduction
Alzheimer’s disease (AD) is expected to double in incidence by 2050 (Hebert et al. 2001),
affecting upwards of 16 million Americans and 90 million people worldwide (Alzheimer’s
Association 2016). Without new treatments, this will represent an unprecedented crisis of
human suffering and financial cost. The attrition rate for AD clinical trials (2002-2012) is
estimated at 99.6% (Cummings et al. 2014), and improved methods of drug discovery are
therefore needed. The underlying pathophysiology of AD is especially poorly understood, and
appears to involve a complex, polygenic, and pleiotropic genetic architecture (Tasaki et al.
2018). Recent studies strongly implicate a crucial role of neuroinflammation in the
pathophysiology of AD (Cao and Zheng 2018). However, broad anti-inflammatory therapies
have not been clinically efficacious against AD. We believe this suggests a pressing need to
better understand the heterogeneity of immune cells in AD, which could translate to
identification of novel drug targets.
Recent single-cell/nucleus RNA-sequencing (scRNA-seq or snRNA-seq) studies have
suggested essential roles for microglia and astrocytes, such as determining the distribution of
immune cell subpopulations in AD (Keren-Shaul et al. 2017; Habib et al. 2020). For example,
disease-associated microglia (DAM) have been identified as a unique microglia subtype
associated with AD (Keren-Shaul et al. 2017), and disease associated astrocytes (DAA) have
been identified as becoming increasingly abundant with progression of AD (Habib et al. 2020).
Astrocytic release of cytokines, the primary immune messenger, influence the microglial
activation state (e.g., CCL2 and ORM2) and also help microglia modulate astrocytic phenotype
and function (e.g., IL1A and TNF) (Jha et al. 2019). A growing body of evidence suggests that
both microglia and astrocytes are exquisitely sensitive to their environment and are affected by
dysregulation of multiple biochemical pathways, such as abnormal lipid metabolism, in AD
pathogenesis (Desale and Chinnathambi 2020). Systematic identification of the underlying
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molecular mechanisms linking DAM and DAA and AD could thus advance understanding of the
underlying biology and offer potential novel drug targets.
Existing data resources, including transcriptomics and interactomics (protein-protein
interactions [PPIs]), have not yet been fully exploited in pursuit of understanding the causal
disease pathways in AD (Fang et al. 2020). With this in mind, integrative analyses of genomics,
transcriptomics, and other omics can enable us to elucidate the cascade of molecular events
contributing to complex neuro-inflammatory mechanisms, including microglia and astrocytes.
We show how these analyses can accelerate the translation of high-throughput singlecell/nucleus omics findings into innovative therapeutic approaches for AD centered on the
interactions of microglia and astrocytes.

Results
Network-based methodology pipeline
In this study, we presented an integrative multi-omics, network-based methodology to uncover
molecular networks of DAM and DAA and to prioritize drug candidates for AD. We integrated
sc/snRNA-seq data from both AD transgenic mouse models and AD patient brains, drug-target
networks, enzyme-metabolite associations, PPIs, along with large-scale patient database
validation (Fig. 1). The whole procedure is divided into 4 components: i) We first assembled the
5 recent sc/snRNA-seq datasets (Supplemental Table S1) covering both microglia and
astrocytes from either AD transgenic mouse models or human brains; ii) We performed
standard bioinformatics analysis for sc/snRNA-seq data, including quality control, cell/nucleus
clustering, and differential expression analysis; iii) We built the molecular network for DAM and
DAA using the state-of-the-art network-based algorithm by integrating sc/snRNA-seq data into
the human protein-protein interactome (Methods); iv) We prioritized repurposed drugs for
potential treatment of AD by identifying those that specifically reverse dysregulated gene
5
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expression of microglia and astrocytes; and (v) We validated top drug candidates using the
state-of-the-art pharmacoepidemiologic observations of a large-scale, longitudinal patient data
(Fig. 1).

Discovery of DAM-specific molecular networks
We compared expression of cell marker genes (Cst7, Lpl, P2ry12 and Cx3cr1) for DAM among
all cell/nucleus clusters (Fig. 2A,B; Supplemental Fig. S1A,B). Here, we used homeostasisassociated microglia (HAM) (Ginhoux and Prinz 2015) as control groups. We found a higher
abundance of DAM nuclei in 5XFAD mice compared to wild-type (WT) mice (p = 0.048, t-test,
Supplemental Table S2; Supplemental Fig. S2A); yet, there was no nucleus abundance
difference for HAM between 5XFAD and WT mice (p = 0.786, Supplemental Fig. S2A). We
observed a similar pattern when considering the scRNA-seq profile, in that the cell abundance
percentage of the DAM in 5XFAD mice was much higher than in WT mice (p = 9.11×10-10,
Supplemental Table S3; Supplemental Fig. S2B). Altogether, both scRNA-seq and snRNAseq profiles show significantly elevated abundance of DAM in 5XFAD compared to WT mice.
We next performed differential expression analyses between DAM and HAM. As expected,
35 AD genes and microglia markers were differentially expressed in DAM compared to HAM in
5XFAD mice, including Apoe, Trem2, Cst7, Lpl, P2ry12 and Cx3cr1 (Supplemental Fig.
S3A,B). We next re-constructed molecular networks (Fig. 2C; Supplemental Fig. S1C) for
DAM based on snRNA-seq (termed snDAMnet) and scRNA-seq (termed scDAMnet) datasets,
using the GPSnet algorithm (Cheng et al. 2019b). The snDAMnet includes 227 PPIs connecting
72 human gene products (e.g., BIN1, HCK, HSP90AA1, IL6ST, PAK1, PRKCD and SYK,
Supplemental Table S4). We assembled AD-associated genes from multiple sources, including
the GWAS catalog (Buniello et al. 2019) and experimental evidences from animal models and
human studies (Piñero et al. 2017). We found that genes in snDAMnet were significantly
enriched in AD-association (adjusted p-value [q] = 5.44×10-11, Fisher's exact test,
6
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Supplemental Table S4), such as Adam10, Bin1, Cd33, and Mapk14. The scDAMnet contains
69 gene products (e.g., Axl, Cst7, Lyn, Mertk and P2ry12, Supplemental Table S5) involving in
97 human PPIs. The scDAMnet is significantly enriched by 27 AD-associated genes (e.g., Apoe,
Ccl3, Ctsd, Inpp5d, and Marcks, q = 1.56×10-8, Supplemental Table S5) as well. We found that
genes in DAMnets are significantly enriched in immune pathways (Supplemental Tables
S4,S5), including multiple key immune modulators related to AD (Fig. 2C; Supplemental Fig.
S1C). Lastly, we illustrated snDAMnet and scDAMnet across 3 selected immune pathways:
fragment crystallizable (Fc) gamma receptor (R)-mediated phagocytosis, the chemokine
signaling pathway, and Th17 cell differentiation (Supplemental Fig. S3C,D), as below.

Fc gamma R-mediated phagocytosis. We identified 15 genes (such as Bin1, Prkcd, Syk, Inpp5d
and Hck) in the Fc gamma R-mediated phagocytosis pathway enriched by either snDAMnet or
scDAMnet (Supplemental Tables S4,S5). Bridging integrator 1 (BIN1), a well-established risk
gene for AD by the International Genomics of Alzheimer's Project, contains a microglia-specific
enhancer and promoter encoded by a genome-wide significant AD variant rs6733839 (Medway
and Morgan 2014). One possible role for BIN1 in DAM function may be gene regulation as a
microglia-specific enhancer and promoter altered by rs6733839 (Corces et al. 2020). Spleen
associated tyrosine kinase (SYK) has also already been shown to play a role in AD pathological
lesions, and has been proposed as a possible drug target for AD (Schweig et al. 2017). Inositol
polyphosphate-5-phosphatase D (INPP5D), identified as one of the genetic risk factors for lateonset AD, also affects AD pathology by regulating microglia (Rosenthal and Kamboh 2014).

Chemokine signaling pathway. Chemokine signaling is enriched in both snDAMnet and
scDAMnet, and these two networks contain 13 genes, including Pak1, Ccl3, Ccl4, Ccr5 and Lyn
(Supplemental Tables S4,S5). P21 (RAC1) activated kinase 1 (PAK1) is dysregulated in AD,
and targeting the PAK signaling pathway has been proposed as a therapeutic strategy for AD
7
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(Ma et al. 2012). C-C motif chemokine ligand 3 and 4 (CCL3 and CCL4), and C-C motif
chemokine receptor 5 (CCR5) (Guedes et al. 2018), have been shown to be upregulated in
adult human microglia or in mouse microglia exposed to Aβ. A recent study observed elevated
activity of LYN proto-oncogene, Src family tyrosine kinase (LYN) in AD patients, and inhibiting
LYN expression prevents Aβ-induced neuronal cell death, suggesting LYN as an potential
therapeutic target for AD (Gwon et al. 2019).

Th17 cell differentiation. The T helper type 17 (Th17) cells are CD4+ T cells that promote a cellmediated immune response against invading bacteria and fungi. We identified 6 genes (Ppp3ca,
Hsp90aa1, Mapk14, Hif1a, Tgfbr2 and Il6st) in the Th17 cell differentiation pathway enriched by
snDAMnet (Supplemental Table S4). With respect to mitogen-activated protein kinase 14
(MAPK14), a mouse model study suggested that inhibiting MAPK14 mitigates AD pathology
(Alam and Scheper 2016). The transcriptional factor hypoxia inducible factor 1 subunit alpha
(HIF1A) was involved in a variety of neurodegenerative diseases, including AD (Zhang et al.
2011). Heat shock protein 90 (HSP90), a chaperone protein, regulates tau pathology by forming
macromolecular complexes with co-chaperones and inhibiting HSP90-mitigated tau pathology
by proteasomal degradation (Campanella et al. 2018).

Discovery of DAA-specific molecular networks
We compared gene expression of 13 DAA cell markers among all nuclei clusters (Fig. 3A,B;
Supplemental Fig. S4A). We found that a normalized nucleus abundance of DAA in 5XFAD
mice is higher than that in WT mice (p = 9.79×10-3, t-test, Supplemental Table S6;
Supplemental Fig. S2C). The mDAAnet (Fig. 3C) includes 407 PPIs connecting 116 proteins
(Supplemental Table S7). The mDAAnet contains 56 AD-associated genes (q = 1.84×10-22,
Fisher's exact test, Supplemental Table S7). A t-distributed stochastic neighbor embedding (tSNE) plot of DAA and non-DAA nuclei are presented in Fig. 4A (Supplemental Fig. S5A). The
8
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hDAAnet contains 16 PPIs connecting 10 proteins (Fig. 4B), including 6 AD-associated proteins
(JUND, MAP1B, FOS, MFGE8, JUNB and JUN, q =8.69×10-4, Fisher's exact test,
Supplemental Table S8).
We further inspected human brain region-specific molecular networks for DAA
(Supplemental Fig. S6). The uniform manifold approximation and projection (UMAP) plots of
DAA and non-DAA nuclei are presented for 2 brain regions of AD patients, including entorhinal
cortex (EC) and superior frontal gyrus (SFG) (Figs. 4C,D). The hDAAECnet contains 43 human
PPIs connecting 26 proteins (Fig. 4E), including 11 AD-associated proteins (q = 3.77×10-4,
Supplemental Table S9). The hDAASFGnet contains 22 PPIs connecting 13 proteins (Fig. 4F),
including 8 AD-associated proteins (q = 1.22×10-4). Molecular networks (hDAAECnet and
hDAASFGnet) between EC and SFG share 9 proteins: DCLK2, HPSE2, HSP90AA1, HSPA1A,
HSPA1B, HSPB1, ID2, JUN and TNC (Figs. 4E,F). For two brain regions, there are no apparent
differences of nucleus abundance percentage across different Braak stages for both DAA and
non-DAA (Supplemental Tables S10-12 and Supplemental Figs. S2D-F).
We next performed functional pathway enrichment analysis and found that genes identified
in DAAnets were significantly enriched in multiple immune pathways (Supplemental Figs. S4B,
S5B,S7A,B). We next turned to investigate gene functions using 2 most significant immune
pathways as examples: IL-17 signaling pathway and antigen processing and presentation. We
identified 7 genes (NFKB1, CEBPB, MAPK1, HSP90AA1, FOS, JUND and JUN) in the IL-17
signaling pathway jointly enriched by all 4 DAA networks from both mouse models and AD
patient brains (Supplemental Tables S7-S9). Nuclear factor kappa B subunit 1 (NFKB1) and
NFKB inhibitor alpha (NFKBIA) control transcription of cytokines and chemokines in astrocytes
and they commonly result in cellular damage or accelerate the production of Aβ in astrocytes
(González-Reyes et al. 2017). Fos proto-oncogene, AP-1 transcription factor subunit (FOS) and
Jun proto-oncogene, AP-1 transcription factor subunit (JUN) are transcriptional factors

9
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mediating functional roles in AD pathobiology (Anderson et al. 1994). There are 3 genes
(HSP90AA1, HSPA1A, and HSPA1B) in the antigen processing and presentation pathway
enriched in either hDAAECnet or hDAASFGnet (Supplemental Table S9). Heat shock protein
90 alpha family class A member 1 (HSP90AA1) has been previously linked to AD (Campanella
et al. 2018). Both heat shock protein family A (Hsp70) member 1A (HSPA1A) (Evgen’ev et al.
2017) and heat shock protein family A (Hsp70) member 1B (HSPA1B) have been shown to
regulate oxidative stress in either mouse model or human AD brains (Clarimón et al. 2003),
suggesting their crucial roles in AD biology and possible treatment approaches.

Alzheimer’s conserved molecular networks between microglia and astrocytes
We next compared the network relationship between DAM and DAA under the human
interactome model (Methods). We only investigated DAM and DAA in transgenic mouse
models as there are lack of well-defined DAM in human AD brains. Using a network proximity
measure (Methods), we found a statistically significant network-based relationship between
DAM and DAA (Fig. 5A; Supplemental Table S13): 1) scDAMnet and mDAAnet (z-score = -1.9,
p=0.029, permutation test) and 2) snDAMnet and mDAAnet (z-score = -4.07, p < 0.001,
permutation test). Mechanistically, we found 8 overlapped genes (APOE, CALM2, CD9, CD63,
CTSB, CTSD, IQGAP1 and LGALS3BP) and 11 commonly enriched immune pathways
between DAM and DAA, such as B cell and T cell receptor signaling and Th17 cell
differentiation (Supplemental Tables S4,S5,S7). For example, Cd9 and Lgals3bp are
differentially expressed in both DAM and DAA of mouse models (Fig. 5B). Galectin-3 binding
protein (LGALS3BP), a secreted glycoprotein, has been reported as a potential marker in aging
(Costa et al. 2020). Two immune pathways (Fc gamma R-mediated phagocytosis and
chemokine signaling) are also enriched in both DAMnets and mDAAnet. Except for LGALS3BP
and CD9 (Fig. 5B), another 7 proteins (AXL, CKB, CSF1R, FGR, HIF1A, INPP5D and RPLP2)
are also shared between scDAMnet and snDAMnet (Fig. 5A). The immune pathway platelet
10
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activation is uniquely enriched in snDAMnet (Supplemental Table S4); yet, IL-17 signaling
pathway and Th1 and Th2 cell differentiation are exclusively enriched in mDAAnet
(Supplemental Table S7). In summary, microglia and astrocytes may trigger neuroinflammation
in AD by a specific molecular network manner.

Metabolites trigger molecular networks between astrocyte and microglia
AD is a pervasive metabolic disorder associated with altered immune responses (Mahajan et al.
2020). We found that metabolic genes from the Kyoto Encyclopedia of Genes and Genomes
(KEGG) (Kanehisa et al. 2017) have a closer network relationship with DAM and DAA networks
in the human interactome (Supplemental Table S13). We next investigated whether
metabolites trigger network perturbation between DAM and DAA under the human proteinprotein interactome model. We constructed a network with 373,320 edges (26,990 metaboliteenzyme associations and 346,330 PPIs). We assembled 155 AD-related metabolites supported
by experimental evidences (Supplemental Table S14) and then re-constructed a subnetwork
consisting of 266 AD-related metabolites and enzymes (Fig. 6A and Supplemental Fig. S8A).
We found 77 enzymes involving in the AD-related metabolites: i) 50 enzymes from DAM; ii)
30 ones from DAA, and iii) 3 enzymes (CTSB, CTSD and APOE) shared between DAM and
DAA (Supplemental Fig. S8B; Supplemental Table S14). Ctsb, encoding cathepsin B in
catabolism and immune resistance (Wu et al. 2017), has elevated expression (Fig. 6B,C) in
both DAM (Fold-Change [FC] = 2.48, q = 8.89×10-84) and DAA (FC = 2.14, q = 3.95×10-43) of
mouse models. Pathway enrichment analysis revealed that 77 enzymes were enriched in
metabolic homeostasis (e.g., glycolysis and gluconeogenesis) and immune signaling pathways
(including IL-3 and IL-5, Supplemental Fig. S8C).
Using a betweenness centrality measure (Supplemental Table S14), we found that fatty
acids and amino acids (Fig. 6A) were two primary types of metabolites involved in molecular
networks between DAM and DAA. For example, Spp1 (Shan et al. 2012) and Fos (Sun et al.
11
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2017), two cellular molecules that promote chronic inflammatory diseases, are significantly overexpressed in both DAM (FC = 5.35, q = 5.51×10-56, Fig. 6D) and DAA (FC = 1.92, q = 1.09×1049

), compared to HAM and non-DAA, respectively. Elaidic acid shows the largest centrality

among all metabolites and is connected with SPP1 and CD44 through involving in fatty acid
metabolism, including phospholipase D family member 3 (PLD3) and galactosidase beta 1
(GLB1) (Kim et al. 2010; Hsieh et al. 2017). Co-expression analysis reveals a slight correlation
of Spp1 and Pld3 in DAM (Spearman’s correlation r = 0.48, p = 0.06, t-test, Fig. 6E). Meanwhile,
arachidonic acid and palmitic acid, two long-chain fatty acids that have well-documented effects
in inducing inflammatory responses (Freigang et al. 2013), are also involved in both DAA and
DAM (Fig. 6A). In summary, these findings suggest functional roles of cellular metabolites
(including fatty acids and amino acids) in the immune interplay of astrocyte and microglia in AD.
Further experimental validations are warranted to verify network-based astrocyte-/microgliaassociated metabolism findings.

Network-based discovery of repurposable drugs
We next turned to identify drug candidates by specifically targeting molecular networks of DAM
and DAA. As shown in Fig. 1, we assembled drug-gene signatures in human cell lines from the
Connectivity Map (CMap) database (Lamb et al. 2006). We posited that if a drug significantly
reverses dysregulated gene expression of DAM or DAA, this drug may have potential in treating
AD. For gene set enrichment analysis (GSEA), we used enrichment score (ES) > 0 and q < 0.05
as a cutoff to prioritize drug candidates. For 1309 drugs from the CMap (Lamb et al. 2006), we
obtained 27, 53, 28, 33, and 94 candidate drugs (ES > 0 and q < 0.05) for snDAMnet,
scDAMnet, hDAAECnet, hDAASFGnet and hDAAnet, respectively (Supplemental Table S15).
As shown in Fig. 7A, we found that network-predicted drugs parsed into seven pharmacological
categories: anti-inflammatory, immunosuppressive, adrenergic beta receptor agonists,
adrenergic alpha-antagonists, antihypertensive, antineoplastic and others. Tretinoin, also known
12
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as all-trans retinoic acid (ATRA), a FDA-approved drug for acute promyelocytic leukemia (APL)
(Warrell et al. 1991), is one of our highest predictions (Supplemental Table S15). Treatment
with tretinoin reduced microglia and astrocyte activities and enhanced cognitive capabilities
(Ding et al. 2008) in a mouse model. Mechanistically, tretinoin directly targets mitogen-activated
protein kinase 1 (MAPK1), LYN and FGR in the scDAMnet (Fig. 7B). Salbutamol, a selective
beta2-adrenergic receptor agonist in treating asthma, is a highly predicted candidate on
snDAMnet (Supplemental Table S15). In vitro studies showed that salbutamol was a direct
inhibitor of Tau filament formation (Townsend et al. 2020). As shown in Fig. 7C, salbutamol
interacts with 3 immune gene products (PRKCD, GRB2 and MAPK14) in snDAMnet, consistent
with mechanistic observations in AD (Russo et al. 2002). Altogether, these network-predicted
drugs (Supplemental Table S15) offer potential candidate compounds to be tested in
nonclinical models or clinical trials in the future.

Validating likely causal drug-AD associations in patient data
We next selected drug candidates using subject matter expertise based on a combination of
factors: (i) strength of the predicted associations; (ii) novelty of the predicted associations with
established mechanisms-of-action; (iii) literature-based evidence in support of prediction; (iv)
availability of sufficient patient data for meaningful evaluation (exclusion of infrequently used
medications). Applying these criteria resulted in fluticasone, an approved glucocorticoid receptor
[NR3C1] agonist for several inflammation-related indications (Lumry 1999). As shown in Fig. 7A,
we found anti-inflammatory agents are the biggest network-predicted drug class. We thus
evaluated fluticasone on AD by analyzing 7.23 million U.S. commercially insured individuals
from the MarketScan Medicare supplemental database. We conducted two cohort analyses to
evaluate the predicted association using state-of-the-art pharmacoepidemiologic analysis: (i)
fluticasone vs. a matched control population (non-fluticasone user), and (ii) fluticasone vs.
mometasone (a stronger NR3C1 agonist (Lumry 1999)). For each comparison, we estimated
13
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the un-stratified Kaplan-Meier curves and conducted propensity score-stratified log-rank tests
using the Cox regression model.
We found that individuals taking fluticasone were at significantly decreased risk for
development of AD (hazard ratio (HR) = 0.86, 95% confidence interval [CI] 0.83-0.89, p <
1.0×10-8, Fig. 8A,C). Propensity score-stratified cohort studies confirmed that usage of
mometasone (a stronger NR3C1 agonist) are significantly associated with reduced risk of AD
compared to fluticasone (HR = 0.74, 95% CI 0.68-0.81, p < 1.0×10-8, Fig. 8B,C). Another
independent database, FDA MedWatch Adverse Events Database, revealed that the
combination of fluticasone and ibuprofen could be a therapeutic option for AD (Lehrer and
Rheinstein 2018). Fluticasone and mometasone are approved steroids to treat asthma and
various allergies with anti-inflammatory, antipruritic, and vasoconstrictive properties (Lumry
1999). Previous studies showed crucial roles of NR3C1 in AD (Canet et al. 2018; de Quervain et
al. 2004), suggesting possible protective effects of fluticasone and mometasone on AD (Fig.
8A-C) via modulating the glucocorticoid signaling.
To further infer the potential mechanisms-of-action of fluticasone and mometasone in AD,
we next integrated networks from drug-target interactions, predicted networks of DAM and DAA,
and human PPIs. Network analysis shows that fluticasone and mometasone indirectly target
glycogen synthase kinase 3 beta (GSK3B) and cyclin-dependent kinase 5 (CDK5) via PPIs in
molecular networks of DAM and DAA (Fig. 8D,E). Lipopolysaccharide-stimulation increased
inflammatory responses in microglia by activating phosphorylation of CDK5 (Na et al. 2015).
CDK5/p35 signaling plays a crucial role in microglial phagocytosis of amyloid beta-protein (Aβ)
(Ma et al. 2013). GSK3B inhibitors reduce microglial migration, inflammation, and inflammationinduced neurotoxicity (Huang and Mucke 2012). Altogether, these observations suggest that
fluticasone and mometasone have potentially protective effects on AD by reducing
glucocorticoid signaling and CDK5/GSK3B mediated inflammation on microglia or astrocytes
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(Fig. 8). Further experimental validation on the network-inferred mechanism-of-action is
warranted.

Discussion
We acknowledged several potential limitations in the current study. Although two snRNA-seq
and scRNA-seq datasets of DAM present consistent expression patterns (Supplemental
Tables S4,S5), snDAMnet and scDAMnet showed a small overlap of differentially expressed
genes. There are several possible explanations. Single-cell and single-nucleus may generate
different cell abundances during cell processing. The procedure for preparing single cell
suspensions from fresh samples may alter the gene expression profiles of individual cells and
change the derived cell type proportions since some cells are more vulnerable to cell
dissociation protocols (Lake et al. 2016).
The network proximity analyses show significant network-based relationships between
DAM and DAA (Supplemental Table S13), including immune pathways enriched by both DAM
and DAA. These findings provide insights into intercellular communication between microglia
and astrocytes; yet, systematic identification of ligand-receptor interactions connecting cell
surface proteins of DAM and DAA may identify previously unrecognized mechanisms regarding
intercellular communication between microglia and astrocytes in AD and offer novel drug targets
for development of anti-inflammatory treatments. There was less significant association
between human and mouse molecular networks (DAM versus DAA) (Supplemental Table S13),
consistent with different immune responses of AD brains between human and mouse models
(Hemonnot et al. 2019). Another study reported distinct gene signatures of DAM between
5XFAD mouse model and human AD brains (Keren-Shaul et al. 2017); furthermore,
upregulation of two mouse DAM marker genes (Lpl and Cst7) cannot be detected in human AD
brains (Zhou et al. 2020b). In addition, divergence of mouse and human cortex may influence
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network-based findings presented here (Hodge et al. 2019). Development of advanced networkbased methodologies to identify conserved cell types and the underlying molecular networks
between human and animal models from evolutionary perspectives is needed in the future.
Finally, potential literature biases regarding PPIs, incompleteness of networks, and small
sample size of sn/scRNA-seq datasets (Supplemental Table S1), may influence our networkbased findings as well.
In summary, we presented a network-based methodology that incorporates large-scale
snRNA-seq and scRNA-seq data from either mouse models or AD patient brains, human PPIs,
enzyme-metabolite associations, and drug target networks, along with large-scale patient-level
data observation. We showed that molecular networks derived from DAM and DAA are
significantly enriched for various well-known immune pathways and AD-related pathobiological
pathways. We demonstrated that the identified molecular networks from DAM and DAA offer
potential targets for drug repurposing and we validated two of network-predicted drugs
(fluticasone and mometasone) in reducing risk of AD using large-scale, longitudinal patient data.
In summary, we believe that the network-based methodology presented here, if broadly applied,
would significantly catalyze innovation in AD drug discovery by utilizing the large-scale singlecell/nucleus omics data.

Methods and Materials
Resources of single-cell/nucleus RNA-sequencing data
The complete sc/snRNA-seq datasets used in this study (Supplemental Table S1) are
available from Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/) database under
accession numbers: GSE98969 (Keren-Shaul et al. 2017), GSE140511 (Zhou et al. 2020b),
GSE143758 (Habib et al. 2020), GSE147528 (Leng et al. 2020), and GSE138852 (Grubman et
al. 2019). One scRNA-seq dataset (GSE98969) contains C57BL/6 (whole brain, n=16) and
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5XFAD (n=16) mice, including 12,288 sequenced cells (Keren-Shaul et al. 2017). Two out of
four snRNA-seq datasets were collected from mouse samples as well (GSE140511 and
GSE143758). Dataset GSE140511 (Zhou et al. 2020b) contained 4 types transgenic male
mouse models, including C57BL/6, 5XFAD, Trem2 knock out C57BL/6 and Trem2 knock out
5XFAD. In this study, we considered the 7-month mouse models which in total sequenced
90,647 nuclei. The second mouse nucleus dataset (GSE143758) contains 2 transgenic mouse
models (C57BL/6 and 5XFAD) from both hippocampus and cortex regions (Habib et al. 2020).
We utilized in total 55,367 nuclei data from the 7-month hippocampus mouse models: (a)
5XFAD (n=5) and (b) C57BL/6 (n=5) (Habib et al. 2020). A human snRNA-seq dataset (Leng et
al. 2020) contains 10 male frozen post-mortem human brain tissues for both superior frontal
gyrus (63,608 nuclei) and entorhinal cortex (42,528 nuclei), including astrocytes, excitatory
neurons, inhibitory neurons, microglia, oligodendrocytes, oligodendrocyte progenitor cells
(OPCs) and endothelial cells (GSE147528) (Leng et al. 2020). A new human snRNA-seq
dataset (Grubman et al. 2019) containing 12 frozen post-mortem human brain tissues (n=6 AD
case and n=6 healthy controls [GSE138852]) from entorhinal cortex regions was further used,
which covers astrocyte, microglia, neuron, oligodendrocyte, OPC, and endothelial cell types. All
statistical analyses were conducted in R (R Core Team, 2020) and the details for bioinformatics
analysis of each dataset were provided in the Supplemental Material.

Building Human Protein-protein interactome
To build the comprehensive human interactome from the most contemporary data available, we
assemble 18 commonly used PPI databases with experimental evidence: (i) binary PPIs tested
by high-throughput yeast-two-hybrid (Y2H) systems (Luck et al. 2020); (ii) kinase-substrate
interactions; (iii) signaling networks; (iv) binary PPIs from three-dimensional protein structures;
(v) protein complexes data; and (vi) carefully literature-curated PPIs. In total, 351,444 PPIs
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connecting 17,706 unique proteins were used in this study (Supplemental Material) and are
free available at https://alzgps.lerner.ccf.org.

Description of GPSnet
GPSnet (Cheng et al. 2019b) takes two inputs: node (gene) scores and a background PPI
network. The node score was defined as follows: for differentially expressed genes (DEGs) with
q ≤ 0.05 and the node scores denote absolute value of log2FC. In order to generate a network
module, GPSnet starts with a randomly selected gene/protein (node). During each iteration, one
of candidate genes (1st order neighbor) that satisfying the following two conditions at the same
time will be added: (1) p-value of the connectivity significance P(i) (Eq. 1) is less than 0.01; (2)
the updated module score is greater than the current one (Eq. 2). We repeated steps (1) and (2)
until no more genes (nodes) can be added to generate each raw module. In this study, we built
~100,000 raw modules ranked by module scores. For each raw module, the corresponding
module score can be computed (Eq. 2) and all raw modules are ranked in decreasing module
score order. The protein frequency is defined based on truncated raw modules. We generated
the final network modules by assembling top raw network modules (Supplemental Tables
S4,S5, S7-S9).


  
 





 




 


    ∑   
√ 1


(1)

(2)

Where, N denotes all proteins/genes in the PPI, n represents numbers of nodes in the module,
dn is the numbers of neighbors of gene i in current module, di is the degree of gene i, MSn+1(i)
denotes the updated module score if adding node i, s(i) denotes the score of node i, M denotes
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the current module, and μ is the average node score of all genes with respect to the PPI
network.

Network proximity
To quantify the relationships of two molecular networks (DAM vs. DAA) in the human
interactome, we adopted the shortest-based network proximity measure (Cheng et al. 2019a) as
below.

d

 

X, Y 




∑
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 , 

(3)

where d(x,y) is the shortest path length between gene x and y from gene sets X and Y,
respectively. To evaluate whether such proximity was significant, the computed network
proximity is transferred into z score form as shown below:



ೞೞ
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Here, μd and σd are the mean and standard deviation of permutation test with 1000 random
experiments. In each random experiment, two random subnetworks Xr and Yr are constructed
with the same numbers of nodes and degree distribution as the given 2 subnetworks X and Y,
separately, in the PPI network.

Network analysis metabolite-enzyme associations
We assembled 155 AD-related metabolites from 12 studies (Supplemental Table S14) and the
Human Metabolome Database (HMDB) (Wishart et al. 2018). All metabolites were identified in
AD-related human samples, including brain tissues, cerebrospinal fluid, and blood. All of these
results are free available in our AlzGPS (Zhou et al. 2021) database,
https://alzgps.lerner.ccf.org. We mapped 240 DAM and DAA disease module genes and the 155
AD-related metabolites to the network and computed the maximal subgraph. Finally, we
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computed the network paths connecting the DAM and DAA gene products on the network as
well as the betweenness centrality of each vertex (Supplemental Material).

Gene Set Enrichment Analysis (GSEA)
We assembled drug-gene signatures from the CMap database containing 6,100 expression
profiles relating 1,309 compounds (Lamb et al. 2006). We utilized GSEA algorithm to predict
drugs across each molecular network of DAM and DAA. Detailed descriptions of GSEA have
been provided in our recent study (Zhou et al. 2020a) and the Supplemental Material.

Enrichment Analysis
All pathway and disease enrichment analyses were conducted using either KEGG 2019 Mouse
or KEGG 2019 Human and DisGeNET (Piñero et al. 2017) from Enrichr (Kuleshov et al. 2016),
respectively.

Pharmacoepidemiologic validation
We used the MarketScan Medicare Claims database from 2012 to 2017 for the
pharmacoepidemiologic analysis. This database includes individual-level procedure codes,
diagnosis codes, and pharmacy claim data for 7.23 million patients. Pharmacy prescriptions of
fluticasone and mometasone were identified using RxNorm and National Drug Code (NDC). For
an individual exposed to fluticasone and mometasone, a drug episode was defined as from drug
initiation to drug discontinuation. A control cohort was selected from patients who were not
exposed to fluticasone. The disease outcome defined by the International Classification of
Disease [ICD] codes (Supplemental Table S16) was time from drug initiation to diagnosis of
AD. The survival curves for time to AD were estimated using a Kaplan-Meier estimator
approach. We used the large number of covariates generated throughout the process to
address clinical scenarios evaluated in each drug cohort. Propensity score stratified survival
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analyses were conducted to investigate the risk of AD between fluticasone users and nonfluticasone users, as well as fluticasone users and mometasone users. Specifically, for each
comparison, the propensity score of taking fluticasone was estimated by using a logistic
regression model, in which the covariates included age, gender, geographical location, and
disease comorbidities. Further, propensity score-stratified Cox-proportional hazards models
were used to conduct statistical inference for the hazard ratios (HR) of developing AD between
two cohorts. All details were provided in the Supplemental Material.

Software availability
All codes written for and used in this study are available from https://github.com/ChengFLab/alzGPSnet and as Supplemental Code.
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Figure legends

Figure 1. A diagram illustrating the network-based framework. A standard single-cell/-nucleus
RNA-sequencing (sc/snRNA-seq) data analysis pipeline includes quality control, clustering
analysis and differentially expressed gene (DEG) analysis. We built the molecular network using
the state-of-the-art network-based algorithm (termed GPSnet) by integrating sc/snRNA-seq data
into the human protein-protein interactome (Methods). Next, we prioritized repurposed drugs for
potential treatment of Alzheimer's disease (AD) by identifying those that specifically reverse
dysregulated gene expression for molecular networks of disease-associated microglia (DAM) or
astrocyte (DAA): if drug-induced up- or down-related genes are significantly enriched in the
dysregulated molecular networks, these drugs will be prioritized as potential candidates for
treatment of AD. Finally, top drug candidates were validated further using a large-scale,
longitudinal patient database. GSEA: Gene-set enrichment analysis; CMap: Connectivity Map.

Figure 2. Discovery of disease-associated microglia (DAM) specific molecular networks for the
transgenic mouse model of Alzheimer's disease (AD). (A) Uniform manifold approximation and
projection (UMAP) plot of clustering 4,389 microglia cells: blue cluster denotes the homeostasis
associated microglia (HAM) and green cluster denotes the DAM. (B) Expression levels
(heatmap) of representative marker genes (up-regulation in DAM: Cst7 and Lpl and downregulation in DAM: P2ry12 and Cx3cr1) in different microglia sub-clusters. (C) A predicted DAM
specific molecular network contains 227 protein-protein interactions (PPIs) connecting 72
proteins. Node sizes are proportional to their corresponding |log2FC| during differential
expression analysis. FC: fold-change. Node (gene/protein) color is coded by known immune
pathways from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Edge color
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is coded by known experimental evidences of PPIs (Methods). Key immune modulators related
to AD are highlighted by bold text.

Figure 3. Discovery of disease-associated astrocyte (DAA) specific molecular networks in
transgenic mouse model of Alzheimer’s disease (AD). (A) T-distributed stochastic neighbor
embedding (t-SNE) plot of clustering 7,748 astrocyte nuclei. Red cluster denotes the disease
associated astrocyte (DAA). (B) Stacked violin plot displaying the expression patterns of 4
representative genes (with the rest 9 genes in Supplemental Fig. S4A) across different
astrocyte sub-clusters. (C) A predicted DAA specific molecular network contains 407 proteinprotein interactions (PPIs) connecting 116 gene products (proteins). Node sizes are proportional
to their corresponding |log2FC| during differential expression analysis. Node color is coded by
known immune pathways from the Kyoto Encyclopedia of Genes and Genomes (KEGG)
database. Edge color is coded by experimental evidences of PPIs. Key immune modulators
related to AD are highlighted by bold text.

Figure 4. Discovery of disease-associated astrocyte (DAA) specific molecular networks from
single-nucleus RNA-sequencing data of human brains with Alzheimer’s disease (AD). (A) Tdistributed stochastic neighbor embedding (t-SNE) plot of clustering 2,119 astrocyte nuclei
between AD patients and healthy controls. (B) An identified DAA specific molecular network
contains 16 protein-protein interactions (PPIs) connecting 10 gene products (proteins). (C)
UMAP plot for 5,599 astrocyte nuclei clustering analysis between AD patients’ (with different
Braak stages) brain entorhinal cortex (EC) region. (D) UMAP plot of clustering 8,348 astrocyte
nuclei for AD patients’ (with different Braak stages) brain superior frontal gyrus (SFG) regions.
(E) An identified DAA specific molecular network containing 43 protein-protein interactions (PPIs)
connecting 26 gene products (proteins) for EC. (F) An identified DAA specific molecular network
containing 22 PPIs connecting 13 genes/proteins for SFG. Node sizes are proportional to their
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corresponding |log2FC|. Node color is coded by known immune pathways from the Kyoto
Encyclopedia of Genes and Genomes (KEGG) database. Edge color is coded by experimental
evidences of PPIs. Key immune modulators related to AD are highlighted by bold text.

Figure 5. Comparison of molecular networks between disease-associated astrocytes (DAA) and
microglia (DAM). (A) Visualization of interplays between DAM and DAA molecular networks in
the human protein-protein interactome network model. (B) Expression levels of Lgals3bp and
Cd9 for homeostatic associated microglia (HAM) versus DAM and DAA versus non-DAA. The
adjusted p-value (q) is computed using the ‘MAST’ function from Seurat R package
(Supplemental Material). All details for gene differential expression analyses are provided in
Supplemental Tables S4,S5,S7.

Figure 6. A metabolite-triggered molecular network between disease-associated astrocyte
(DAA) and microglia (DAM). (A) A highlighted subnetwork of the metabolite-enzyme network
between DAM and DAA in the human protein-protein interactome network model; (B-C)
Expression of Ctsb is significantly elevated in (B) DAM (GSE98969) and (C) DAA (GSE143758),
compared to homeostatic associated microglia (HAM) and non-DAA, respectively. (D)
Expression of Spp1 is significantly elevated in DAM (GSE98969) compared with HAM. Each dot
represents one cell/nucleus; (E) Spearman’s correlation analysis shows that Spp1 and Pld3
have a slight coordinated change trends in DAM. Gene expression is counted by the average
Unique Molecular Identifier (UMI) count.

Figure 7. Network-based discovery of repurposable drug candidates for AD by specifically
reversing gene expression of disease-associated microglia (DAM) and disease-associated
astrocytes (DAA). (A) Selected drugs that specifically target five different DAM or DAA
molecular networks. Drug are grouped by five different classes (immunological, respiratory,
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neurological, cardiovascular, and cancer (Supplemental Table S12)) defined by the first-level
of the Anatomical Therapeutic Chemical (ATC) codes. Four high-confidence drugs (fluticasone,
mometasone, salbutamol, and tretinoin) were highlighted. (B) Proposed mechanism-of-actions
for two selected drugs (tretinoin and salbutamol) by drug-target network analysis.

Figure 8. Retrospective case-control analysis reveals that usage of fluticasone and
mometasone is significantly associated with reduced likelihood of AD in a longitudinal patient
database with 7.23 million subjects. Two comparison analyses were conducted including: (A)
fluticasone (a glucocorticoid receptor agonist) vs. a matched control population (non-fluticasone
users) and (B) mometasone (a stronger glucocorticoid receptor agonist) vs. fluticasone. For
each comparator, we estimated the un-stratified Kaplan-Meier curves, conducted propensity
score stratified (n strata = 10) rank test and applied Cox models after adjusting all possible
confounding factors, including age, gender, race, and disease comorbidities (Supplemental
Table S16). (C) Hazard ratios (HR) and 95% confidence interval (CI) for two drug cohort studies.
Propensity score stratified Cox-proportional hazards models were used to conduct statistical
inference for the hazard ratios. (D,E) Proposed mechanism-of-action for treatment of AD by
fluticasone and mometasone using drug-target network analysis.
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